Whitefort Capital Management Files Amendment 4 for Arbutus Biopharma, Discloses Total Return Swap

Whitefort Capital Management, LP and its affiliates filed an amendment to their Schedule 13D regarding their investment in Arbutus Biopharma Corp (ABUS). As of the event date on April 24, 2026, the reporting persons beneficially own 15,794,261 common shares, representing approximately 8.0% of the company, a slight decrease from the previously reported 8.1%. The filing details recent market activity, including the purchase of 3,500,000 shares between April 23 and April 24, followed by the sale of 3,500,000 shares on April 27, 2026. Simultaneously, Whitefort Master Fund entered into a cash-settled total return swap agreement with Nomura Global Financial Products Inc. covering 3,500,000 notional shares at a reference price of $4.28. While this swap provides economic exposure to an additional 1.8% of the outstanding shares (bringing total economic exposure to 9.8%), the reporting persons disclaim beneficial ownership of the shares underlying the swap. The aggregate purchase price for the directly held shares was approximately $41.3 million.